Posted by Michael Wonder on 04 Dec 2017
Brexit may mean British patients have to wait longer for life-saving drugs with the NHS forced to shell out more for them, pharmaceutical bosses warn
3 December 2017 - Pharmaceutical boss Mark Hicken was addressing the House of Lords last week.
British patients may have to wait longer for life-saving treatments – with the NHS forced to shell out more for them – because of Brexit, drugs bosses have warned.
Pulling out of the European Union risks delaying the process of getting vital new medicines approved, according to senior executives at some of the world’s biggest pharmaceutical companies.
Delivering their stark warning to the House of Lords last week, they said Brexit could require firms to go through two approval processes – one for Europe and another for the UK.
